Recent Releases
-
Tempus AI Inc, collaboration agreement15 September 2025 07:06 GMT
-
Holding(s) in Company2 September 2025 12:46 GMT
-
Holding(s) in Company1 September 2025 11:18 GMT
-
Holding(s) in Company29 August 2025 09:25 GMT
-
Holding(s) in Company26 August 2025 11:45 GMT
Featured documents
Recent Events
-
Renalytix Third Quarter Fiscal Year 2024 Earnings Call and Webcast15 May 2024 08:30 ET
-
BTIG Conference13 February 2024 - 14 February 2024 ET
-
Renalytix First Quarter Fiscal Year 2024 Earnings Call and Webcast17 November 2023 08:30 ET
-
Renalytix Fourth Quarter Fiscal Year 2023 Earnings Call and Webcast28 September 2023 08:30 ET
Who we are
Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Our goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through our KidneyIntelX platform.
Company metrics
Leading the market year after year
- Addressing one of the largest and costliest unmet needs in healthcare
- Listed on AIM (November, 2018) and OTCQB (October, 2024)
- FDA Approves KidneyIntelX.dkd™ (June 2023)
LATE BREAKING NEWS:
RENALYTIX ANNOUNCES COLLABORATION WITH TEMPUS AI
Definitive agreement to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within the Tempus US network of healthcare institutions.